The Relationship between Thioredoxin-2, Systemic Immune-inflammatory Index, and Short-term Adverse Cardiovascular Events in Septic Cardiomyopathy

Yafei Zhang; Dahe  Han; Chun Yang; Yali Chao; Qing Xiao; Chenliang Sun; Yi Guo

doi:10.18502/ijaai.v24i5.19746

Yafei Zhang Department of Critical Care, Xuzhou Mining Group General Hospital (The Second Affiliated Hospital of Xuzhou Medical University), Xuzhou, China
Dahe Han Department of Critical Care, Xuzhou Mining Group General Hospital (The Second Affiliated Hospital of Xuzhou Medical University), Xuzhou, China
Chun Yang Department of Geriatric Cardiology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China
Yali Chao Department of Critical Care, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
Qing Xiao Department of Critical Care, The Second Peoples Hospital of LianYunGang, LianYunGang, China
Chenliang Sun Department of Critical Care, The Affiliated Hospital of Nantong Medical University, Nantong, China
Yi Guo Department of Critical Care, Xuzhou Mining Group General Hospital (The Second Affiliated Hospital of Xuzhou Medical University), Xuzhou, China

DOI: https://doi.org/10.18502/ijaai.v24i5.19746

Keywords: Cardiovascular diseases; Cardiomyopathy; Neutrophils; Septic; Thioredoxins

Abstract

To explore the relationship between thioredoxins (Trx) -2, systemic-immune inflammatory index (SII), and short-term major adverse cardiac events (MACE) in septic cardiomyopathy (SCM).

A retrospective study was conducted on 98 SCM patients admitted to Affiliated Jinling Hospital, Medical School of Nanjing University Emergency Intensive Care Unit (EICU) from July 2022 to June 2024. Patients underwent routine blood tests and data assessment upon admission. Based on the occurrence of MACE by day 28, patients were divided into the MACE group and the non-MACE (N-MACE) group. Clinical data were collected, and logistic regression, along with restricted cubic spline models, analyzed the relationships between SII, Trx-2, and MACE risk in SCM patients.

Among the 98 SCM patients included, there were 35 (35.71%) in the MACE group and 63 (64.29%) in the N-MACE group. Logistic regression analysis showed that elevated SII and serum Trx-2 levels correlated with an increased risk of MACE within 28 days post-admission for SCM patients. Restricted cubic spline analysis revealed a linear dose-response relationship between both SII and Trx-2 levels with short-term MACE risk in SCM. The ROC curve showed AUC values of 0.869 for LVEF, 0.881 for SII, while combining SII + Trx-2 yielded 0.926 (95% CI: 0.862-0.989), with specificity at 83.98% and sensitivity at 98.80%.

The abnormal increase of serum SII and Trx-2 levels in SCM patients is related to the occurrence of MACE within 28 days after admission. The risk of MACE increases with the increase of serum SII and Trx-2 levels.